XOMA files Pulmokine financials for $20M cash acquisition closed Nov 26, 2024

XOMA Royalty Corp

XOMA acquired Pulmokine for $20M cash at closing; historical audited and unaudited financials filed.
Pulmokine 2023 revenue $10M (milestone) and net income $7.95M; cash $708K at year-end.
Pro forma condensed combined balance sheet and income statements filed as Exhibit 99.4.
Pulmokine is a biopharma developing inhaled PDGFR inhibitor for pulmonary arterial hypertension.
Exhibits include audited FY2023, unaudited 9M2024 financials, and independent auditor consent.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.